Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service cholecystectomy & appendectomy cases in Rhode Island: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (255 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 4 | 426 | 51% |
| 2020 | 5 | 406 | 53% |
| 2021 | 5 | 409 | 57% |
The highest-volume laparoscopic cases; identifies every active general surgeon. Professional codes (what the surgeon bills): CPT 47562, 47563, 44970, 47600; the hospital bills MS-DRG 417, 418, 419, 338, 339, 340, 397, 398, 399.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Rhode Island; 4 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 96 | 5,762−3.7%/yr | −3.7%/yr | 3.3 | 2% | 6,020 in 2030+0.7%/yr |
| Pennsylvania | 95 |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Hernia repair | 6 | 457−5.4%/yr | −5.4%/yr | 5.40.9× | 0% | 350 in 2030−4.5%/yr |
| Colorectal resection |
Cholecystectomy & appendectomy in every state, and its device makers · Every procedure market in Rhode Island · Every state · Compare with New York
| 2024 |
| 359 |
| 66% |
| 2025 est. | ≈ 330 | – |
| 2026 est. | ≈ 340 | – |
| 2022 | 4 | 379 | 60% |
| 2023 | 5 | 405 | 64% |
| 2024 | 4 | 359 | 66% |
| 2025 from claims | – | 330 267–387 | 67% |
| 2026 forecast | – | 343 268–430 | 66% |
| 2027 forecast | – | 346 256–457 | 66% |
| 2028 forecast | – | 349 247–482 | 67% |
| 2029 forecast | – | 353 240–505 | 67% |
| 2030 forecast | – | 356 233–528 | 67% |
In 2025, 47% inpatient hospital, 53% hospital outpatient.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient |
|---|---|---|
| 2026 · ~340 | ~160 | ~180 |
| 2027 · ~350 | ~170 | ~180 |
| 2028 · ~350 | ~170 | ~180 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: inpatient hospital about 48% (47% in 2025), hospital outpatient about 52% (53% in 2025).
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| 5,634−4%/yr |
| −4%/yr |
| 4.3 |
| 1% |
| 5,840 in 2030+0.6%/yr |
| New Jersey | 81 | 3,400−3.2%/yr | −3.2%/yr | 3.3 | 1% | 3,540 in 2030+0.7%/yr |
| Massachusetts | 60 | 3,162−3.7%/yr | −3.7%/yr | 3.4 | 0% | 3,520 in 2030+1.8%/yr |
| Connecticut | 13 | 1,125−6.5%/yr | −6.5%/yr | 3.5 | 0% | 1,160 in 2030+0.5%/yr |
| New Hampshire | 6 | 766−3%/yr | −3%/yr | 3.4 | 2% | 990 in 2030+4.4%/yr |
| Maine | 3 | 578−9.6%/yr | −9.6%/yr | 3.8 | 0% | 630 in 2030+1.4%/yr |
| Vermont | 2 | 272−7%/yr | −7%/yr | 2.4 | 0% | 430 in 2030+8%/yr |
| 0 |
| 116−12%/yr |
| −12%/yr |
| 1.30.8× |
| 0% |
| 230 in 2030+12%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Stryker leads with 96% of company spending on these surgeons in 2025, +5 pts on 2024.
In 2025, 3 companies reported engagement with Rhode Island’s surgeons worth $14K in consulting, speaking, meals and travel tied to these products, about $3,540 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 33 clearances and approvals in the category, 2 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.